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Aims_The progression of pathological left ventricular remodeling leads to cardiac 
dysfunction and contributes to the occurrence of malignant arrhythmias and sudden 
cardiac death. The underlying molecular mechanisms remain unclear, however. Our aim 
was to examine the role of the renin-angiotensin system (RAS) in the mechanism 
underlying arrhythmogenic cardiac remodeling using a transgenic mouse expressing a 
cardiac-specific dominant-negative form of neuron-restrictive silencer factor 
(dnNRSF-Tg). This mouse model exhibits progressive cardiac dysfunction leading to 
lethal arrhythmias.  
Methods and results_Subcutaneous administration of aliskiren, a direct renin inhibitor, 
significantly suppressed the progression of pathological cardiac remodeling and 
improved survival among dnNRSF-Tg mice while reducing arrhythmogenicity. Genetic 
deletion of the angiotensin type 1a receptor (AT1aR) similarly suppressed cardiac 
remodeling and sudden death. In optical mapping analyses, spontaneous ventricular 
tachycardia (VT) and fibrillation (VF) initiated by breakthrough-type excitations 
originating from focal activation sites and maintained by functional re-entry were 
observed in dnNRSF-Tg hearts. Under constant pacing, dnNRSF-Tg hearts exhibited 
markedly slowed conduction velocity, which likely contributes to the arrhythmogenic 
substrate. Aliskiren treatment increased conduction velocity and reduced the incidence 
of sustained VT. These effects were associated with suppression of cardiac fibrosis and 
restoration of connexin 43 expression in dnNRSF-Tg ventricles. 
Conclusion_Renin inhibition or genetic deletion of AT1aR suppresses pathological 
cardiac remodeling that leads to the generation of substrates maintaining VT/VF and 
reduces the occurrence of sudden death in dnNRSF-Tg mice. These findings 
demonstrate the significant contribution of RAS activation to the progression of 
arrhythmogenic substrates. 
 







Ventricular tachyarrhythmia is a major cause of morbidity and mortality in patients with 
heart failure. Sudden cardiac death, generally preceded by the development of 
ventricular tachycardia (VT) or fibrillation (VF), accounts for approximately 50% of 
deaths among heart failure patients1. Although it appears that multiple mechanisms, 
including abnormal impulse initiation (the trigger) and a pre-existing arrhythmogenic 
substrate for initiation and maintenance of re-entry, are coordinately involved in the 
development of lethal arrhythmias, the precise molecular mechanisms mediating the 
initiation and maintenance of VT and VF in failing hearts remains largely undefined2, 3.  
We previously reported that a transcriptional repressor, neuron-restrictive silencer 
factor (NRSF, also named REST) is an important regulator of the fetal cardiac gene 
program, and generated transgenic mice cardiac-specifically expressing a 
dominant-negative mutant of NRSF (dnNRSF-Tg)4. These dnNRSF-Tg mice exhibit 
progressive cardiomyopathy and sudden arrhythmic death, beginning at about 8 weeks 
of age4. In addition, dnNRSF-Tg hearts exhibit increased expression of fetal cardiac 
genes commonly observed in hypertrophied and failing hearts in both rodents and 
humans, suggesting this mouse model is a representative and useful model of 
non-ischemic cardiomyopathy accompanied by lethal arrhythmias. In our earlier studies, 
we demonstrated that blockade of fetal type cardiac ion channels (T-type Ca2+ channels 
(TCC) or HCN channels) reduced the incidence of sudden death among dnNRSF-Tg 
mice5, 6. However, this approach did not prevent the pathological remodeling observed 
in dnNRSF-Tg ventricles, which suggests these channels are involved largely in the 
generation of the trigger for the arrhythmias, not the substrate.  
The renin-angiotensin system (RAS) is a pivotal signaling pathway often 
involved in the development of cardiovascular diseases. Indeed, activation of RAS is 
associated with an increased risk for ventricular tachyarrhythmias3; however the effect 
of RAS signaling on the occurrence of lethal arrhythmias and their underlying 
mechanisms is less certain. In this study, we used optical mapping analysis of cardiac 
action potentials to assess the role of RAS activation in the mechanism underlying the 
remodeling that leads to generation of arrhythmogenic substrates in dnNRSF-Tg mice. 
We found that both pharmacological blockade of RAS activation using a direct renin 
inhibitor or genetic deletion of the angiotensin II type 1a receptor (AT1aR) significantly 
ameliorated pathological cardiac remodeling and suppressed the generation of 
arrhythmogenic substrates and sudden cardiac death in dnNRSF-Tg mice. These 
beneficial effects were achieved, at least in part, through attenuation of cardiac fibrosis 




the RAS contributes critically to the progression of arrhythmogenic remodeling that 
leads to generation of arrhythmogenic substrates in non-ischemic cardiomyopathy 






An expanded Methods section is available in Supplemental Material Online. 
 
2.1. Animal experiments  
The animal care and all experimental protocols were reviewed and approved by the 
Animal Research Committee at Kyoto University Graduate School of Medicine, and 
conformed to the US National Institute of Health Guide for the Care and Use of 
Laboratory Animals. Beginning at 16 weeks of age, male dnNRSF-Tg or wild-type 
(WT) mice were treated for 12 weeks with aliskiren (23 mg/kg/day S.C.) or vehicle 
(untreated) using osmotic minipumps (ALZET osmotic pumps, DURECT Corporation, 
Cupertino, CA, USA) according to the manufacture’s protocol. The doses of the drugs 
were chosen based on earlier reports and our preliminary studies7. Aliskiren was 
provided by Novartis Pharma AG (Basel, Switzerland). In another experiment, male 
dnNRSF-Tg and WT mice were treated for 6 weeks with aliskiren at the same dose (23 
mg/kg/day S.C.), beginning when they were 12 weeks of age.  
To obtain dnNRSF-Tg;AT1aR-/- mice and their control dnNRSF-Tg;AT1aR+/+ 
littermates, dnNRSF-Tg mice (C57BL/6 background) were bred with AT1aR knockout 
mice (C57BL/6 background). AT1aR-/- mice were described in an earlier report8.  
For the isolation and analysis of hearts, mice were anesthetized with 3.0 % of 
isoflurane and sacrificed by cervical dislocation. For the implantation of osmotic 
minipumps and radio frequency transmitters, mice were anesthetized with sodium 
pentobarbital injected intraperitoneally (40mg/kg). 
 
2.2. Measurement of plasma hormone concentrations 
Plasma renin activity and aldosterone concentrations were measured using a Gamma 
Coat Plasma Renin Activity kit (Dade Behring, Tokyo, Japan) and a SPAC-S 
aldosterone kit (Daiichi Radioisotope Labs, Tokyo, Japan). 
 
2.3. Measurement of hemodynamics and cardiac function  
Blood pressure, echocardiography and hemodynamic parameters were measured as 
previously described4. 
 
2.4. Histological analysis 
Consecutive tissue sections from hearts fixed in 10% formalin were stained with 
hematoxylin and eosin (HE) and with Masson’s trichrome using standard staining 




(1:100 dilution, #3512, Cell Signaling Technology).  
 
2.5. Quantitative PCR and Western blot analysis 
Relative mRNA levels were determined using quantitative real-time PCR, as previously 
described6. Western blot analysis was carried out using lysates from mouse ventricles, 
as described previously6. 
 
2.6. Intracardiac electrophysiology 
Intracardiac electrophysiological studies were performed on mice intubated and 
anesthetized, as described previously4. 
 
2.7. Optical mapping 
The procedures for optical mapping were essentially the same as described previously9. 
Briefly, hearts were perfused on a Langendorff apparatus with modified Krebs-Ringer 
solution at 37°C. The tissue was then loaded with a voltage-sensitive dye, di-4-ANEPPS 
(4 M, 10min), and fluorescence images (256  256 pixels) were recorded at 1000 
frames/s using a solid-state image-sensing digital video camera (Fastcam-Max, Photron, 
Japan). The data obtained were analyzed using software written in our laboratory9.  
 
2.8. Statistical Analysis 
Survival was analyzed using the Kaplan-Meier method with the log-rank test.  
Unpaired t tests were used for comparisons between two independent groups, while 
paired t tests were used for comparisons between two groups that were correlated. 
One-way ANOVA with post hoc Fisher’s tests was used for comparisons among three 
groups, and two-way ANOVA with post hoc Fisher’s tests was used for comparison 
among four groups containing two variables. Numbers of premature ventricular 
contractions (PVCs) and episodes of VT were compared between two groups using the 
non-parametric Mann-Whitney test. The incidences of VT among dnNRSF-Tg mice 
during the intracardiac electrophysiological and optical mapping studies were analyzed 





3.1. Direct renin inhibition improves survival among dnNRSF-Tg mice 
Plasma renin activity, aldosterone concentrations and angiotensin II concentrations were 
all significantly higher in dnNSRF-Tg mice than their wild type littermates (WT) 
(Figure 1A and B, and Supplemental Figure S1A ). To determine the role played by 
RAS in the progression of cardiomyopathy and sudden arrhythmic death in dnNRSF-Tg 
mice, we subcutaneously administered aliskiren, a direct renin inhibitor, for 12 weeks at 
23 mg/kg/day, beginning when the mice were 16 weeks of age (Figure 1C). The dose of 
aliskiren did not affect blood pressure in dnNRSF-Tg mice, which had significantly 
lower systolic blood pressures than in WT mice (Figure 1D and E). Heart rates were 
significantly slower in dnNRSF-Tg than WT mice, but aliskiren did not affect heart 
rates (Figure 1F). As expected, aliskiren significantly reduced plasma renin activity and 
angiotensin II concentrations (Figure 1A and Supplemental Figure S1A) and markedly 
suppressed the increase in plasma aldosterone levels otherwise seen in dnNRSF-Tg 
mice (Figure 1B). This indicates that sufficient systemic RAS inhibition was achieved 
with aliskiren at the dose used. In addition, to evaluate local RAS activity, we also 
measured ventricular expression of several mRNAs encoding RAS-related proteins, 
including renin, angiotensin converting enzyme (ACE), angiotensinogen, AT1aR and 
(pro) renin receptor, and measured cardiac angiotensin II concentrations. Among these, 
expression of ACE mRNA was significantly increased in the ventricles of untreated 
dnNRSF-Tg mice, but this enhancement was reversed by aliskiren (Figure 1G). 
Ventricular angiotensin II concentrations were higher in untreated dnNRSF-Tg mice, 
and aliskiren also significantly suppressed that increase (Supplemental Figure S1B). 
Expression of AT1aR mRNA and protein levels did not significantly differ among the 
four groups (Figure 1H and Supplemental Figure S1C), nor did expression of renin, 
angiotensinogen or (pro) renin receptor mRNA (Supplemental Figure S1D-F). 
Collectively, the effects of aliskiren in dnNRSF-Tg mice significantly improved 
survival (Figure 1I). 
 
3.2. Renin inhibition prevents the progression of pathological ventricular 
remodeling in dnNRSF-Tg mice 
We next examined the effects of aliskiren on cardiac structure and function. 
Heart-to-body weight ratios in untreated dnNRSF-Tg, which are higher than in WT 
mice4, 5, were significantly reduced by aliskiren (Figure 2A). Body weights were not 
significantly affected by aliskiren, irrespective of genotype (Supplemental Figure S2A). 
Echocardiographic analysis performed with conscious mice showed that the ejection 




were both increased in 28-week-old untreated dnNRSF-Tg mice, as compared to 
age-matched WT mice, which is consistent with earlier findings (Table 1 and 
Supplemental Figure S2B)5, 10. Aliskiren prevented the deterioration of these 
echocardiographic parameters during the treatment period (Table 1 and Supplemental 
Figure S2C-E).  
Hemodynamic measurements performed on 22-week-old mice after left cardiac 
catheterization showed that left ventricular (LV) end-diastolic pressure was significantly 
higher and +dP/dt was significantly lower in untreated dnNRSF-Tg than WT hearts, as 
described previously (Table 1 and Supplemental Figure S3A and B)4. -dP/dt was also 
significantly depressed in untreated dnNRSF-Tg (Table 1 and Supplemental Figure 
S3B), and aliskiren significantly improved all these hemodynamic parameters (Table 1 
and Supplemental Figure S3A and B).  
To evaluate aliskiren’s ability to prevent pathological cardiac remodeling in 
younger dnNRSF-Tg mice, we also treated 12-week-old mice with aliskiren for 6 weeks 
(from 12 to 18 weeks of age). Examination following the treatment showed that 
aliskiren partially, but significantly, prevented the increase in heart-to-body weight 
ratios and deterioration in cardiac function in dnNRSF-Tg mice. (Supplemental Figure 
S4A-E) 
Histological analysis of ventricular cross-sections revealed left ventricular (LV) 
dilatation and thinning of the ventricular wall in untreated dnNRSF-Tg hearts, which 
were both prevented by aliskiren (Figure 2B). Mean myocyte size was significantly 
greater in untreated dnNRSF-Tg than WT hearts, but aliskiren significantly reduced 
myocyte size in dnNSRF-Tg hearts (Figure 2C and 2D).  
The results summarized above suggest aliskiren prevents pathologic cardiac 
remodeling in dnNRSF-Tg mice. To further confirm that idea, we evaluated the 
expression of fetal cardiac genes as sensitive markers for pathological remodeling. 
When we measured the gene expression of atrial natriuretic peptide (ANP), β-myosin 
heavy chain (MHC) and skeletal α-actin mRNA in ventricles from 28-week-old mice, 
we found their expression levels to be significantly higher in untreated dnNRSF-Tg than 
WT mice (Figure 2E-G). Moreover, the increase in the expression of these genes in 
dnNRSF-Tg mice was significantly suppressed by aliskiren (Figure 2E-G). Conversely, 
transcription of the -MHC and sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 
(SERCA2) genes was reduced in untreated dnNRSF-Tg mice, but was significantly 
restored by treatment with aliskiren (Figure 2H and Supplemental Figure S5A). Finally, 
expression of CACNA1H, encoding the TCC  subunit, and HCN2 and 4, all of which 




expression levels did not significantly differ between untreated mice and those treated 
with aliskiren (Supplemental Figure S5B-D)4.   
 
3.3. Renin inhibition suppresses malignant arrhythmias in dnNRSF-Tg mice 
We next used a telemetric monitoring system to examine the effects of aliskiren on the 
incidence of arrhythmias. As previously described, dnNRSF-Tg mice exhibited frequent 
PVCs and VTs, both of which were significantly suppressed by aliskiren (Figure 3A 
and B). We previously showed that at a similar age WT mice showed no such 
arrhythmias5. Because aliskiren ameliorated the progression of pathological cardiac 
remodeling without affecting NRSF-regulated fetal cardiac ion channel gene expression, 
we hypothesized that the drug primarily suppressed the generation of arrhythmogenic 
re-entrant substrates in dnNRSF-Tg hearts. To test that idea, we carried out an in vivo 
intracardiac electrophysiological analysis in dnNRSF-Tg mice. As previously shown, 
dnNRSF-Tg hearts were highly susceptible to induction of VT (Figure 3C), whereas no 
induction of VT was detected in WT hearts, whether left untreated (n=5) or 
administered aliskiren (n=7). Furthermore, aliskiren strongly suppressed susceptibility 
of dnNRSF-Tg hearts to VTs, suggesting aliskiren prevented the generation of 
arrhythmogenic re-entrant substrates (Figure 3C).  
 
3.4. Deletion of AT1aR also prevents pathological cardiac remodeling and sudden 
death in dnNRSF-Tg mice 
To further confirm that inhibition of RAS signaling is responsible for aliskiren-induced 
suppression of cardiac remodeling and sudden death in dnNRSF-Tg mice, we 
genetically deleted AT1aR from the mice by crossing dnNRSF-Tg mice with AT1aR 
knockout mice (AT1aR-/-)8. Heart-to-body weight ratios, which were significantly 
higher in dnNRSF-Tg;AT1aR+/+ than WT mice (Figure 2A), were significantly reduced 
in dnNRSF-Tg;AT1aR-/- mice (Figure 3D and E). Subsequent echocardiographic 
analysis revealed that LV diastolic dimension, LV systolic dimension and ejection 
fraction were all significantly better in dnNRSF-Tg;AT1aR-/- than 
dnNRSF-Tg;AT1aR+/+ mice (Figure 3F-H and supplemental Table S1). Ventricular 
expression of ANP, β-MHC and skeletal α-actin mRNA, which was significantly higher 
in dnNRSF-Tg;AT1aR+/+ than WT mice (Figure 2E-G), was significantly lower in 
dnNRSF-Tg;AT1aR-/- than dnNRSF-Tg;AT1aR+/+ mice (Figure 3I-K). Conversely, 
levels of -MHC and SERCA2 mRNA, which were reduced in dnNRSF-Tg;AT1aR+/+ 
mice (Figure 2H and Supplemental Figure S5A), were significantly restored in 
dnNRSF-Tg;AT1aR-/- mice (Figure 3L and Supplemental Figure S6A). Mean myocyte 




dnNRSF-Tg;AT1aR+/+ nice (Supplemental Figure S6B). Expression of ACE mRNA in 
dnNRSF-Tg;AT1aR-/- ventricles was significantly weaker than in 
dnNRSF-Tg;AT1aR+/+ mice (Supplemental Figure S6C). Cardiac expression of AT1aR 
mRNA was undetectable in dnNRSF-Tg;AT1aR-/- mice (Supplemental Figure S6D). 
More importantly, dnNRSF-Tg;AT1aR-/- mice had better survival rates than 
dnNRSF-Tg;AT1aR+/+ mice (Figure 3M). We previously reported no significant 
difference in cardiac structure, function or arrhythmicity between AT1aR-/- mice and 
WT mice under basal conditions8.  
 
3.5. Optical mapping reveals the arrhythmogenic mechanisms in dnNRSF-Tg 
hearts and the effects of renin inhibition on the electrophysiological properties  
To investigate the electrophysiological mechanism underlying the occurrence of 
malignant arrhythmias in dnNRSF-Tg and the effect of RAS inhibition on those 
arrhythmias, we used high-resolution epicardial optical mapping of membrane voltage 
to analyze action potential signals in Langendorff-perfused hearts from WT and 
dnNRSF-Tg9. In all of the hearts from untreated dnNRSF-Tg, we observed spontaneous 
sustained and non-sustained VT/VFs, whereas no VT/VFs were observed in control WT 
hearts (Figure 4A and B).  Hearts from dnNRSF-Tg treated with aliskiren continued to 
show spontaneous PVCs and non-sustained VTs at a reduced frequency, but the 
incidence of sustained VT was markedly lower than in untreated dnNRSF-Tg hearts 
(Figure 4A and B). The epicardial activation pattern and optical action potential signals 
recorded from Langendorff-perfused ventricles of untreated dnNRSF-Tg revealed that 
VT/VFs were initiated following breakthrough-type excitations, which originated from 
focal activation sites and then propagated over the entire ventricle (Figure 4C and 
Supplemental Online Video S1). Optical signals near the focal activation sites showed 
early afterdepolarization (EAD)-type triggered activity (Figure 4C and Supplemental 
Online Video S1). Furthermore, while breakthrough-type excitations were observed 
during the initial phase of VT/VFs, complex interplay between focal and re-entrant 
activity was involved in the maintenance of sustained VT/VFs in untreated dnNRSF-Tg 
hearts (Figure 4D and Supplemental Online Video S2). Under constant pacing, action 
potential duration (APD) was significantly prolonged and conduction velocity was 
markedly slower in untreated dnNRSF-Tg than WT (Figure 4E-G, and Supplemental 
Online Video S3). Consequently, the wavelength was significantly shorter in untreated 
dnNRSF-Tg than WT, and favored the formation and stability of functional re-entry 
(Figure 4H). In aliskiren-treated dnNRSF-Tg, the prolongation of APD was partially 
reversed and conduction velocity was completely restored, resulting in complete 




could account for the dramatic reduction in incidence of sustained VT (Figure 3B and 
4B).   
   
3.6. Renin inhibition suppresses cardiac fibrosis and restores connexin43 
expression in dnNRSF-Tg ventricles 
To begin to determine the molecular mechanism responsible for the conduction delay 
and the generation of arrhythmogenic substrates in dnNRSF-Tg and its reversal by 
aliskiren, we examined the contribution of cardiac fibrosis, which is known to slow 
conduction and create a substrate vulnerable to re-entry3, 11. Masson's trichrome staining 
revealed that interstitial fibrosis in dnNRSF-Tg was significantly diminished by 
aliskiren (Figure 5A and B). Consistent with that finding, the expression of 
fibrosis-related genes, including transforming growth factor- (TGFβ)-1, TGFβ-3, 
collagen type 1 1, fibronectin, tissue inhibitor of metalloproteinase (TIMP)-1 and 
matrix metalloproteinase (MMP)-2 was significantly elevated in untreated dnNRSF-Tg 
(Figure 5C-H), and the TIMP-1/MMP2 ratio was significantly increased (Figure 5I). 
These increases were almost completely blocked in dnNRSF-Tg mice treated with 
aliskiren (Figure 5C-I). Furthermore, the increase in interstitial fibrosis seen in 
dnNRSF-Tg ventricles was significantly suppressed in dnNRSF-Tg;AT1aR-/- ventricles 
(Supplemental Figure S6E). In addition, the expression of TGFβ-1, TGFβ-3, collagen 
type 1 1, fibronectin, TIMP-1 and MMP-2 mRNA and the TIMP-1/MMP2 ratio were 
all significantly reduced in dnNRSF-Tg;AT1aR-/- ventricles, as compared to 
dnNRSF-Tg;AT1aR+/+ ventricles (Supplemental Figure S6F-L). 
We also focused on the expression of connexin 43 (Cx43), which is the principle 
component of gap junctions in the adult cardiac ventricle12. Cx43 deficiency reportedly 
leads to a slowing of conduction velocity and to ventricular arrhythmias13. 
Immunohistochemical labeling showed that Cx43 expression, measured as the 
Cx43-positive area, was significantly weaker in untreated dnNRSF-Tg than WT 
ventricles, and that aliskiren restored Cx43 expression in dnNRSF-Tg hearts (Figure 6A 
and B). We observed that in WT ventricles, Cx43 is expressed almost entirely in 
troponin T-positive cardiac myocytes and that in aliskiren-treated dnNRSF-Tg ventricles, 
Cx43 expression is restored to troponin T-positive cardiac myocytes (Supplemental 
Figure S7A). Consistent with that finding, Western blot analysis showed that Cx43 
levels are significantly lower in untreated dnNRSF-Tg than untreated WT ventricles, but 
that aliskiren restored Cx43 expression in dnNRSF-Tg ventricles (Figure 6C and D). 
Levels of Cx43 mRNA did not significantly differ among untreated WT, untreated 
dnNRSF-Tg and aliskiren-treated dnNRSF-Tg hearts, suggesting the altered Cx43 




aliskiren treatment did not significantly affect levels of Cx43 protein (Supplemental 
Figure S7C and D). Similar restoration of Cx43 was observed in dnNRSF-Tg;AT1aR-/- 
ventricles (Supplemental Figure S7E). It is known that Cx43 levels and its function are 
regulated by phosphorylation by several kinases14. For example, phosphorylation of two 
serine residues, Ser279/282, by p42/44 MAPK leads to a reduction in gap junction 
communication and initiates Cx43 turnover14. When we examined the phosphorylation 
status of Cx43 in WT and dnNRSF-Tg ventricles using several phospho-specific 
antibodies, we found that the level of Cx43 Ser279/282 phosphorylation was higher in 
untreated dnNRSF-Tg than untreated WT ventricles, and that the levels in dnNRSF-Tg 
ventricles were significantly reduced by aliskiren (Figure 6E and F). In WT mice, 
aliskiren treatment did not significantly affect Cx43 Ser279/282 phosphorylation 
(Supplemental Figure S7C and F). Consistent with the increased Cx43 Ser279/282 
phosphorylation, levels of both activated and total p42/44 MAPK were higher in 
untreated dnNRSF-Tg than untreated WT ventricles, but they were reduced by aliskiren 
treatment in dnNRSF-Tg ventricles (Figure 6E). The relative levels of activated 
(phosphorylated) p42/44 MAPK normalized to total p42/44 MAPK were also higher in 
untreated dnNRSF-Tg than untreated WT ventricles, but they too were reduced by 
aliskiren treatment in dnNRSF-Tg ventricles (Supplemental Figure S7G). In WT mice, 
aliskiren treatment did not significantly affect either activated or total p42/44 MAPK 
levels (Supplemental Figure S7C and H). These results demonstrate that cardiac fibrosis 
and reduced expression of Cx43, at least in part, contribute to the conduction delay in 
dnNRSF-Tg ventricles, and that preventing these events is associated with restoration of 





In the present study, we demonstrated that pharmacological blockade of RAS signaling 
using the renin inhibitor aliskiren significantly reduced pathological cardiac remodeling 
and the resultant increase in the incidences of malignant arrhythmias and sudden death 
in dnNRSF-Tg mice, a mouse model of non-ischemic cardiomyopathy with lethal 
arrhythmias4. The mode of death in these model mice is sudden and without overt 
edema, pleural effusion or apparent lung congestion, and all of the telemetry data 
obtained at the time of death indicates VT/VF to be the cause4. Optical mapping of 
cardiac action potentials revealed that EAD-type triggered activity induced by excessive 
APD prolongation and functional re-entry associated with decreased conduction 
velocity contribute to the initiation and maintenance of VT/VF in failing hearts in 
dnNRSF-Tg. Aliskiren treatment significantly reversed the slowed conduction velocity, 
thereby disrupting the maintenance of re-entry. Prevention of the decline in Cx43 
expression and the suppression of interstitial fibrosis presumably mediated the observed 
aliskiren-induced reduction of arrhythmogenicity, at least in part. Genetic deletion of 
AT1aR in dnNRSF-Tg similarly ameliorated pathological LV remodeling and prolonged 
the survival. Collectively, these results clearly indicate that by increasing interstitial 
fibrosis and reducing expression of Cx43, RAS signaling acts as a key promoter of 
remodeling that leads to the generation of arrhythmogenic substrates in failing hearts, 
and thus contributes to the occurrence of lethal arrhythmias.  
We previously showed that expression of fetal cardiac ion channels (i.e., TCCs and 
HCN channels) is significantly increased in dnNRSF-Tg ventricles and that inhibition of 
these channels improves survival by reducing the incidence of malignant arrhythmias 
without ameliorating cardiac remodeling5, 6. This suggests these channels do not 
predominantly contribute to the pathological cardiac remodeling seen in this mouse 
model, but are instead involved in the triggering of arrhythmias; i.e., the increased 
triggering of arrhythmias reflects ion channel alterations initiated by the genetic 
inhibition of NRSF. By contrast, aliskiren significantly ameliorated pathological cardiac 
remodeling in dnNRSF-Tg mice, which in turn reduced the incidences of malignant 
arrhythmias and sudden death. Optical mapping analysis revealed that aliskiren 
improved conduction velocity and strongly suppressed the incidence of sustained VT in 
dnNRSF-Tg hearts. Together with the results of our earlier studies, these findings 
suggest the increased triggering of arrhythmias reflects ion channel alterations initiated 
by the genetic inhibition of NRSF. Moreover, the progression of arrhythmogenic 
substrates, which is mediated by RAS activation, contributes synergistically to the 




A link between RAS signaling, altered Cx43 regulation and increased 
arrhythmicity has been suggested in several studies8, 15, 16. However, that link had never 
been evaluated in a model of heart failure showing spontaneous malignant arrhythmias 
and sudden cardiac death, and the underlying electrophysiological mechanisms 
remained unreported. By using dnNRSF-Tg mice, we were able to reveal the critical 
contribution made by the RAS to the generation of malignant arrhythmias and the 
underlying arrhythmogenic mechanisms, which involve the dysregulation of Cx43 and 
increased cardiac fibrosis, both of which contribute to a reduction of conduction 
velocity. 
Renin was recently reported to affect cardiovascular function and remodeling 
through the (pro) renin receptor independently of the generation of angiotensin II17. It 
may be that the effects of the renin inhibitor aliskiren observed in the present study are 
mediated in part via this alternative pathway. However, it is unlikely that pathway is a 
major contributor to the observed effect of aliskiren in this study, as deletion of AT1aR 
from dnNRSF-Tg mice produced phenotypes similar to aliskiren treatment. Given the 
differences in the experimental conditions used for pharmacological inhibition with 
aliskiren and genetic deletion of AT1aR, it is difficult to precisely address the 
differential contributions made by renin and angiotensin II to cardiac remodeling in this 
study. Aldosterone, downstream of RAS, is also involved in pathological cardiac 
remodeling. Indeed, in several clinical trials, administration of a mineral corticoid 
receptor antagonist suppressed sudden cardiac death in patients with heart failure18. In 
the present study, aliskiren suppressed plasma aldosterone in dnNRSF-Tg mice nearly to 
the levels seen in control WT mice. Elucidation of the precise roles played by each 
component of the RAS could potentially serve as the basis for development of a more 
effective strategy to prevent sudden cardiac death in heart failure. In that context, NRSF 
reportedly regulate aldosterone synthase (CYP11B2) and 11-hydroxylase (CYP11B1) 
gene expression in adrenal cells19. As cardiac expression of these genes is very weak 
and does not significantly differ between dnNRSF-Tg and WT ventricles (unpublished 
observations), we think it is unlikely that elevated cardiac aldosterone synthase directly 
induced by NRSF inhibition is responsible for the increased plasma aldosterone levels 
seen in dnNRSF-Tg mice.  
In the ASTRONAUT trial, the effect of aliskiren on post-discharge outcomes 
among patients hospitalized for heart failure was tested by adding the drug to the 
standard therapy, which included ACE inhibitors or angiotensin receptor blockers and 
-blockers20. Under those conditions, aliskiren showed no significant effect on primary 
endpoints. In our study, aliskiren was administered to untreated mice with cardiac 




that adding aliskiren to the standard therapy improves post-discharge outcomes in 
non-diabetic patients hospitalized for heart failure21. Future investigation is needed to 
confirm the potential benefits of renin inhibition under these conditions.  
In this study we did not assess the sodium current (INa), which is also an 
important determinant of conduction velocity in ventricular myocardium3, because the 
amplitude of INa is too large to correctly measure under physiological conditions in 
isolated myocytes. The role of changes in INa in the failing hearts is somewhat 
controversial, however3. Nevertheless, as the resting membrane potentials in ventricular 
myocytes from dnNRSF-Tg are more depolarized than those from WT5, there is a 
possibility that reduced availability of INa is also involved in the conduction delay 
observed in the dnNRSF-Tg ventricular myocardium. In addition, we did not perform a 
detailed analysis of the effects of RAS blockade on cardiac myocyte kinetics and 
mechanics in isolated cells; we used echocardiography and LV catheterization to 
evaluate cardiac systolic and diastolic function in vivo. Furthermore, because it is 
impossible to completely rule out that some dnNRSF-Tg mice (especially older mice) 
died due to congestive heart failure, despite the arrhythmias, there is still a possibility 
that RAS inhibition may also prevent this mode of death, in addition to sudden 
arrhythmic death, in dnNRSF-Tg mice. We anticipate that further investigation will lead 
to the development of more effective pharmacological approaches to preventing lethal 
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Figure 1. Renin inhibition prolongs survival among dnNRSF-Tg (Tg) mice.  A and B, 
Plasma renin activity (A) and aldosterone concentrations (B) in 28-week-old 
WT and dnNRSF-Tg mice, with or without aliskiren (n = 9 for untreated WT, 
6 for aliskiren-treated WT, 10 for untreated Tg and 6 for aliskiren-treated Tg 
mice). C, Diagram illustrating the renin-angiotensin system and the action of 
aliskiren on that system. AT1R: angiotensin type 1 receptor. AT2R: 
angiotensin type 2 receptor. ACE: angiotensin-converting enzyme. D, E and F, 
Systolic blood pressure (D), diastolic blood pressure (E) and heart rates (F) in 
28-week-old WT and dnNRSF-Tg mice, with and without aliskiren (Ali) 
(n=16 for untreated control WT, 9 for WT with aliskiren, 5 for untreated 
control Tg and Tg with aliskiren). G and H, Gene expression of cardiac ACE 
(G) and AT1aR (H) in WT and dnNRSF-Tg, with or without aliskiren (n=10 
for untreated and aliskiren-treated WT, 5 for untreated Tg and 8 for 
aliskiren-treated Tg mice). All data are shown as dot plots and means±SEM. 
*p<0.05. I. Kaplan-Meyer survival curves for dnNRSF-Tg, with or without 
aliskiren.  Aliskiren treatment began when the mice were 16 weeks of age 
and lasted 12 weeks: *p<0.05 (n = 54 for untreated Tg, 28 for aliskiren-treated 
Tg, and 10 for untreated and aliskiren-treated WT mice).  
 
Figure 2.  Effects of renin inhibition on cardiac remodeling in dnNRSF-Tg mice.  A, 
Heart weight-to-body weight ratios (HW/BW) in 28-week-old WT and Tg, 
with or without aliskiren (Ali) (n = 16 for untreated WT, 12 for 
aliskiren-treated WT, 11 for untreated Tg and 10 for aliskiren-treated Tg mice). 
B-D, Histological analysis of hearts from 28-week-old WT and dnNRSF-Tg, 
with or without aliskiren: HE, hematoxylin-eosin staining. B, HE-stained 
coronal sections of hearts. Scale bars, 1 mm. C, Photomicrographs of 
HE-stained left ventricular sections. Scale bars, 40 m. D, Areas of individual 
myocardial cells in left ventricles. Bars are mean myocyte areas measured in 
100 cells in each group (n=3 for untreated WT and WT with aliskiren, 5 for 
untreated Tg and Tg with aliskiren). E-H, Relative levels of ANP (E), β-MHC 
(F), skeletal α-actin (G) and α-MHC (H) mRNA in hearts from 28-week-old 
WT and dnNRSF-Tg, with or without aliskiren (Ali) (n = 10 for untreated and 
aliskiren-treated WT, 5 for untreated Tg and 8 for aliskiren-treated Tg mice). 
Unless indicated otherwise, aliskiren treatment began when the mice were 16 




means±SEM. *p<0.05.   
 
Figure 3.  Effects of renin inhibition on arrhythmias and effects of genetic deletion of 
the angiotensin II type 1a receptor (AT1aR) on cardiac remodeling and 
survival in dnNRSF-Tg mice.  A and B, Numbers of PVCs (A) and VTs (B) 
recorded using a telemetry system in 22-week-old dnNRSF-Tg, with or 
without 6 weeks of aliskiren treatment. Data are shown as dot plots. *p<0.05 
using Mann-Whitney test (n=3 for untreated Tg and 4 for Tg with aliskiren).  
C, Incidence of VTs induced during intracardiac electrophysiology studies in 
22-week-old Tg, with or without 6 weeks of aliskiren treatment.  Upper 
numbers, numbers of mice with induced VT; lower numbers, total numbers of 
mice tested. *p<0.05 using Fischer’s exact test. D and E, Heart weight-to-body 
weight ratios (HW/BW) (D) and body weights (BW) (E) in 18-week-old 
dnNRSF-Tg;AT1aR+/+ and dnNRSF-Tg;AT1aR-/- mice (n = 8 for 
dnNRSF-Tg;AT1aR+/+ and 9 for dnNRSF-Tg;AT1aR-/- mice). F-H, 
Echocardiographic parameters in 16-week-old dnNRSF-Tg;AT1aR+/+ and 
dnNRSF-Tg;AT1aR-/- mice. LV diastolic dimension (Dd) (F), LV systolic 
dimension (Ds) (G) and ejection fraction (EF) (H) are shown (n=10 each). I-L, 
Relative levels of ANP (I), β-MHC (J), skeletal α-actin (SKA) (K) and α-MHC 
(L) mRNA in hearts from 18-week-old dnNRSF-Tg;AT1aR+/+ and 
dnNRSF-Tg;AT1aR-/- mice (n=6 each). All data in D-L are shown as dot plots 
and means±SEM. *p<0.05. NS: not significant. M, Kaplan-Meyer survival 
curves for dnNRSF-Tg; AT1aR+/+ and dnNRSF-Tg; AT1aR-/- (n=30 for 
dnNRSF-Tg; AT1aR+/+ and 20 for dnNRSF-Tg; AT1aR-/-). *p<0.05. 
 
Figure 4. Optical mapping analysis of VT/VF in dnNRSF-Tg mice. A, Representative 
bipolar electrocardiographs (ECG) from Langendorff-perfused hearts from 
WT, untreated dnNRSF-Tg (Tg) and dnNRSF-Tg treated for 6 weeks with 
aliskiren (Tg+Ali). The ECG from the untreated dnNRSF-Tg heart shows 
both repetitive non-sustained VT and sustained VT/VF, as indicated. The 
ECG from the aliskiren-treated dnNRSF-Tg heart shows a ventricular 
premature complex (ventricular bigeminy). B, Incidence (%) of mice showing 
spontaneous sustained and non-sustained VT/VF in perfused hearts from WT 
(n=4), Tg (n=10) and Tg+Ali (n=9). Mice used in the optical mapping 
experiments were 20-24 weeks of age. Black bars indicate the incidences of 
mice showing sustained VT/VF; gray bars indicate the incidences of mice 




mice showing sustained VT/VF significantly differed between Tg and 
TG+Ali (p<0.05 using Fischer’s exact test). C, Simultaneous recording of a 
bipolar ECG (left, top) and optical action potential signals (left, bottom) 
during the onset of non-sustained and sustained VTs in a perfused 
dnNRSF-Tg heart. The optical signals were recorded from the site indicated 
by the asterisk (*) in the right panel. Right, isochrone activation map showing 
a breakthrough-type focal activation pattern during the onset of sustained VT.  
D, Representative phase snap shot during a long-lasting VT episode in a 
dnNRSF-Tg heart. Complex interplay between figure-eight type re-entrant 
activity (circle and round arrows) and focal discharge (asterisk and arrows) 
was involved in the maintenance of arrhythmia. A bipolar ECG is shown 
above the image. E, Superimposed representative optical action potential 
signals recorded from WT, Tg and Tg+Ali hearts. The APD90 (ms) for each 
action potential is indicated. F-H, Graphs showing the APD90 (F), conduction 
velocity (G) and wavelength (H) of the optical action potential signals in 
hearts of WT, Tg and Tg+Ali (n=3 each) during constant pacing (4 Hz). In 
F-H, graphs are shown as dot plots and means±SEM. *p<0.05.   
 
Figure 5.  Renin inhibition suppresses cardiac fibrosis in dnNRSF-Tg mice.  A, 
Histological analysis of hearts from WT and dnNRSF-Tg, with or without 
aliskiren. Shown are photomicrographs of Masson-trichrome-stained sections 
of left ventricle. Scale bars, 50 m. B, Graphs showing the % collagen area in 
hearts from WT and dnNRSF-Tg, with or without aliskiren (n=6 for untreated 
WT, 7 for WT with aliskiren, 5 for untreated Tg and 8 for Tg with aliskiren). 
C-H, Relative levels of transforming growth factor--1 (Tgfb1) (C), Tgfb3 (D), 
collagen type 1 1 (Col1α1 ) (E), fibronectin (FN1) (F), tissue inhibitor of 
metalloproteinase-1 (TIMP1) (G) and matrix metalloproteinase-2 (MMP2) (H) 
mRNA in hearts from WT and dnNRSF-Tg, with or without aliskiren. I, 
TIMP-1/MMP2 ratios in hearts from WT and dnNRSF-Tg, with or without 
aliskiren. In all graphs, n=10 for untreated WT and WT with aliskiren, 5 for 
untreated Tg and n=8 for Tg with aliskiren. Aliskiren treatment began when 
the mice were 16 weeks of age and lasted 12 weeks. All data are shown as dot 
plots and means±SEM. *p<0.05.  
 
Figure 6. Renin inhibition prevents the reduction in connexin (Cx) 43 expression in 
dnNRSF-Tg hearts. A, Immunostaining of Cx43 in hearts from WT and 




Graph showing the levels of Cx43 expression measured as Cx43-positive area 
(n = 2 for untreated WT and aliskiren-treated WT, 4 for untreated Tg and 3 for 
aliskiren-treated Tg mice). C, Western blot analysis of Cx43 and GAPDH 
expression in the ventricles from WT and dnNRSF-Tg, with or without 
aliskiren treatment. D, Relative Cx43 levels in the ventricles of WT (n=2) and 
dnNRSF-Tg, with (n=4) or without aliskiren (n=4). Cx43 levels were 
normalized to those of GAPDH. The relative Cx43 level in untreated WT mice 
were assigned a value of 1.0. E, Representative Western blot analysis of 
Ser279/282-phosphorylated Cx43, unphosphorylated Cx43, phosphorylated 
p42/44 MAPK, total p42/44 MAPK and GAPDH in the ventricles of WT and 
dnNRSF-Tg, with or without aliskiren. F, Relative Ser279/282-phosphorylated 
Cx43 levels normalized to the total Cx43 in ventricles from WT (n=2) and 
dnNRSF-Tg, with (n=4) or without aliskiren (n=4). Aliskiren treatment began 
when the mice were 16 weeks of age and lasted 12 weeks. All data are shown 






Table I. Echocardiographic and hemodynamic parameters in WT and dnNRSF-Tg 
mice, with or without aliskiren treatment  
 
            WT                  dnNRSF-Tg         
   Untreated  Ali Untreated  Ali 
Echocardiographic data         
  Heart Rate (/min) 719±9.7 711±12.6 586±12.1 588±16.7 
  LVDd (mm) 2.8±0.14 2.7±0.12 4.2±0.27 3.7±0.12 
  LVDs (mm) 1.1±0.098 1.2±0.067 3.6±0.29 2.9±0.17 
  IVST (mm) 0.62±0.03 0.63±0.04 0.52±0.04 0.57±0.03 
  PWT (mm) 0.65±0.04 0.65±0.03 0.50±0.03 0.48±0.02 
  EF (%) 93.0±1.1 91.5±0.8 36.0±4.2* 52.9±4.4*† 
  FS (%) 59.7±2.3 56.2±1.5 14.2±2.2* 22.8±2.4*† 
Hemodynamic data 









  LVEDP (mm Hg) 3.2±0.6 2.3±0.4 8.6±2.1* 2.2±1.3† 
  dP/dt (mm Hg/sec) 9189±347 8871±753 3922±898* 7091±766† 
  -dP/dt (mm Hg/sec) -5789±421 -6418±569 -2966±585* -6375±704† 
 
Values are means ± SEM. Echocardiographic parameters were measured in 28-week-old 
WT and dnNRSF-Tg mice, with or without 12 weeks of aliskiren treatment. 
Hemodynamic parameters were measured in 22-week-old WT and dnNRSF-Tg mice, 
with or without 6 weeks of aliskiren treatment. Numbers of mice tested in 
echocardiographic analyses were 11 for untreated control WT and 10 for WT with 
aliskiren, untreated dnNRSF-Tg and dnNRSF-Tg with aliskiren.  Numbers of mice 
catheterized were 3 for untreated control WT and untreated dnNRSF-Tg and 4 for WT 
with aliskiren and dnNRSF-Tg with aliskiren. Ali, mice treated with aliskiren; LVDd, 
left ventricular diastolic dimension; LVDs, left ventricular systolic dimension; IVST, 
interventricular septum thickness; PWT, posterior wall thickness; EF, ejection fraction; 
FS, fractional shortening; LVSP, left ventricular systolic pressure; LVEDP, left 
ventricular end diastolic pressure; dP/dt, first derivative of pressure. *p<0.05 vs. 
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